Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive transcriptome analysis of osteoclasts with the SIK3 deletion and pterosin B treatment.

ABSTRACT: Comprehensive transcriptome analysis of osteoclasts with the SIK3 deletion and pterosin B treatment.

PROVIDER: PRJNA980570 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24834800_1.fastq.gz	Fastqsanger.gz
	SRR24834800_2.fastq.gz	Fastqsanger.gz
	SRR24834801_1.fastq.gz	Fastqsanger.gz
	SRR24834801_2.fastq.gz	Fastqsanger.gz
	SRR24834802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Comprehensive transcriptome analysis of osteoclasts with the SIK3 deletion and pterosin B treatment.

Project description:Maintenance of bone homeostasis and the balance between bone resorption and formation are crucial for maintaining skeletal integrity. Osteoclasts are responsible for bone resorption and play a vital role in this process. The role of salt-inducible kinase 3 (SIK3) in osteoclast differentiation and maturation and its potential as a therapeutic target for osteoporosis remain poorly understood. Here, we generated osteoclast-specific Sik3 conditional knockout (cKO) mice and investigated the effects of SIK3 deletion on bone homeostasis. Our findings revealed increased bone mineral density and an osteopetrosis phenotype in Sik3 cKO mice, indicating the involvement of SIK3 in bone resorption. Furthermore, we examined the effect of pterosin B, an SIK3 inhibitor, on osteoclast differentiation. Pterosin B treatment inhibits osteoclast differentiation in vitro, reduces the number of multinucleated osteoclasts, and suppresses bone resorption. Therefore, in this study, to better understand the molecular mechanism of SIK3 in osteoclast differentiation and maturation, we performed gene expression profiling of bone marrow monocytes from SIK3 deletion and pterosin B treated mice using RNA sequencing (RNA-seq).

2024-07-21 | GSE234221 | GEO

Whole transcriptome analysis of osteoclasts after treatment with or without etelcalcetide

Project description:Whole transcriptome analysis of osteoclasts after treatment with or without etelcalcetide

| PRJNA1020088 | ENA

Whole transcriptome analysis of osteoclasts after treatment with or without etelcalcetide

Project description:Phosphate binders, vitamin D analogs, and calcimimetics have recently been used to control the disturbed mineral metabolism in chronic kidney disease-mineral and bone disorder (CKD-MBD). Etelcalcetide , a new calcimimetic agent approved by is considered by patients due to its convenience as an intravenous form which easily affordable during dialysis sessions. In this study, we evaluated the effects of etelcalcetide on osteoclasts.

2024-10-10 | GSE243811 | GEO

Comparison expression data from wild-type and NFATc1-deficient osteoclasts

Project description:Genetic deletion of Nfatc1 in mice results in profound osteoclast-poor osteopetrosis, a high bone mass state caused by a lack of osteoclast activity. We hypothesized that the family of NFATc1 regulated transcripts in the osteoclast would be enriched for genes associated with osteoclast function. We used microarrays profile gene expression in wild-type and NFATc1-deficient osteoclasts generated in vitro to identify NFATc1-dependent transcripts in osteoclasts. Bone marrow macrophages from wild-type and mice with an induced deficiency of NFATc1 (NFATc1 fl/fl MxCre+ mice where NFATc1 excision was induced by polyIC treatment) were cultured ex vivo in MCSF and RANKL for 3 days. 2 biological replicates were assayed for each genotype.

2012-08-18 | E-GEOD-37219 | biostudies-arrayexpress

Expression profile of osteoclasts treated with bisphosphonates

Project description:Bisphosphonates are the mainstay of therapy worldwide for osteoporosis. They inhibit the activities of the osteoclasts, the bone resorption cells. While bisphosphonates are known to block farnesyl pyrophsophate synthase to exert their anti-resorptive action, the detailed mechanism is not well understood. Examining the change in expression profile before and after bisphosphonate treatment in the osteoclasts might shed some light on the biological pathways that are perturbed. Osteoclastic precursor cells were treated with (or without) bisphosphonates (alendronate or risedronate) during their differentiation into mature osteoclasts.

2014-11-06 | E-GEOD-63009 | biostudies-arrayexpress

Effect of TET deletion on the global DNA methylation status of osteoclasts

Project description:Effect of TET deletion on the global DNA methylation status of osteoclasts

| PRJNA656813 | ENA

Effect of BMS-582949 treatment on gene expression in osteoclasts

Project description:Effect of BMS-582949 treatment on gene expression in osteoclasts

| PRJNA1051041 | ENA

Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts

Project description:The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signaling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P3. Finally, pharmacologic treatment with the non-selective S1P receptor agonist FTY720 causes increased bone formation in wildtype, but not in S1P3-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo, and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts. Osteoclasts of wildtype and Calcr-/- C57Bl/6 mice were treated with Calcitonin and compared to the non-treated osteoclasts of wildtype or Calcr-/- mice, respectively.

2014-10-19 | E-GEOD-60761 | biostudies-arrayexpress

Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment

Project description:Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment

| PRJNA589865 | ENA

Microarray analysis of Macrophages and Osteoclasts

Project description:Comparaison of genes expression between bone marrow derived macrophages and osteoclasts in C57BL/6J mice

2016-09-17 | GSE86998 | GEO